These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 34826353)

  • 1. Improved attention linked to sustained phenylalanine reduction in adults with early-treated phenylketonuria.
    Bilder DA; Arnold GL; Dimmock D; Grant ML; Janzen D; Longo N; Nguyen-Driver M; Jurecki E; Merilainen M; Amato G; Waisbren S
    Am J Med Genet A; 2022 Mar; 188(3):768-778. PubMed ID: 34826353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluating change in diet with pegvaliase treatment in adults with phenylketonuria: Analysis of phase 3 clinical trial data.
    Rohr F; Burton B; Dee A; Harding CO; Lilienstein J; Lindstrom K; MacLeod E; Rose S; Singh R; van Calcar S; Whitehall K
    Mol Genet Metab; 2024 Mar; 141(3):108122. PubMed ID: 38184920
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pegvaliase for the treatment of phenylketonuria: Results of a long-term phase 3 clinical trial program (PRISM).
    Thomas J; Levy H; Amato S; Vockley J; Zori R; Dimmock D; Harding CO; Bilder DA; Weng HH; Olbertz J; Merilainen M; Jiang J; Larimore K; Gupta S; Gu Z; Northrup H;
    Mol Genet Metab; 2018 May; 124(1):27-38. PubMed ID: 29653686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two-year interim safety and efficacy of pegvaliase in Japanese adults with phenylketonuria.
    Ishige M; Ito T; Hamazaki T; Kuwahara M; Lee L; Shintaku H
    Mol Genet Metab; 2023 Nov; 140(3):107697. PubMed ID: 37717412
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term comparative effectiveness of pegvaliase versus medical nutrition therapy with and without sapropterin in adults with phenylketonuria.
    Burton BK; Clague GE; Harding CO; Kucuksayrac E; Levy DG; Lindstrom K; Longo N; Maillot F; Muntau AC; Rutsch F; Zori RT
    Mol Genet Metab; 2024 Jan; 141(1):108114. PubMed ID: 38142628
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pegvaliase for the treatment of phenylketonuria: Results of the phase 2 dose-finding studies with long-term follow-up.
    Burton BK; Longo N; Vockley J; Grange DK; Harding CO; Decker C; Li M; Lau K; Rosen O; Larimore K; Thomas J;
    Mol Genet Metab; 2020 Aug; 130(4):239-246. PubMed ID: 32593547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pegvaliase for the treatment of phenylketonuria: Final results of a long-term phase 3 clinical trial program.
    Harding CO; Longo N; Northrup H; Sacharow S; Singh R; Thomas JA; Vockley J; Zori RT; Bulloch Whitehall K; Lilienstein J; Lindstrom K; Levy DG; Jones S; Burton BK
    Mol Genet Metab Rep; 2024 Jun; 39():101084. PubMed ID: 38694233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term safety and efficacy of pegvaliase for the treatment of phenylketonuria in adults: combined phase 2 outcomes through PAL-003 extension study.
    Longo N; Zori R; Wasserstein MP; Vockley J; Burton BK; Decker C; Li M; Lau K; Jiang J; Larimore K; Thomas JA
    Orphanet J Rare Dis; 2018 Jul; 13(1):108. PubMed ID: 29973227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction, titration, and maintenance dosing regimen in a phase 2 study of pegvaliase for control of blood phenylalanine in adults with phenylketonuria.
    Zori R; Thomas JA; Shur N; Rizzo WB; Decker C; Rosen O; Li M; Schweighardt B; Larimore K; Longo N
    Mol Genet Metab; 2018 Nov; 125(3):217-227. PubMed ID: 30146451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pegvaliase for the treatment of phenylketonuria: A pivotal, double-blind randomized discontinuation Phase 3 clinical trial.
    Harding CO; Amato RS; Stuy M; Longo N; Burton BK; Posner J; Weng HH; Merilainen M; Gu Z; Jiang J; Vockley J;
    Mol Genet Metab; 2018 May; 124(1):20-26. PubMed ID: 29628378
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term comparative effectiveness of pegvaliase versus standard of care comparators in adults with phenylketonuria.
    Zori R; Ahring K; Burton B; Pastores GM; Rutsch F; Jha A; Jurecki E; Rowell R; Harding C
    Mol Genet Metab; 2019; 128(1-2):92-101. PubMed ID: 31439512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PTC923 (sepiapterin) lowers elevated blood phenylalanine in subjects with phenylketonuria: a phase 2 randomized, multi-center, three-period crossover, open-label, active controlled, all-comers study.
    Bratkovic D; Margvelashvili L; Tchan MC; Nisbet J; Smith N
    Metabolism; 2022 Mar; 128():155116. PubMed ID: 34973284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized, placebo-controlled, double-blind study of sapropterin to treat ADHD symptoms and executive function impairment in children and adults with sapropterin-responsive phenylketonuria.
    Burton B; Grant M; Feigenbaum A; Singh R; Hendren R; Siriwardena K; Phillips J; Sanchez-Valle A; Waisbren S; Gillis J; Prasad S; Merilainen M; Lang W; Zhang C; Yu S; Stahl S
    Mol Genet Metab; 2015 Mar; 114(3):415-24. PubMed ID: 25533024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pegvaliase therapy for phenylketonuria: Real-world case series and clinical insights.
    Scala I; Brodosi L; Gueraldi D; Manti F; Rovelli V; Zuvadelli J; Agnelli G; Cazzorla C; Nardecchia F; Giammanco A; Biasucci G
    Mol Genet Metab; 2024 May; 142(1):108151. PubMed ID: 38522180
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of high-protein meal plus aspartame ingestion on plasma phenylalanine concentrations in obligate heterozygotes for phenylketonuria.
    Curtius HC; Endres W; Blau N
    Metabolism; 1994 Apr; 43(4):413-6. PubMed ID: 8159095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Of mice and men: Plasma phenylalanine reduction in PKU corrects neurotransmitter pathways in the brain.
    Berguig GY; Martin NT; Creer AY; Xie L; Zhang L; Murphy R; Pacheco G; Bullens S; Olbertz J; Weng HH
    Mol Genet Metab; 2019 Dec; 128(4):422-430. PubMed ID: 31648944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nutrition status of adults with phenylketonuria treated with pegvaliase.
    Viau K; Wessel A; Martell L; Sacharow S; Rohr F
    Mol Genet Metab; 2021 Aug; 133(4):345-351. PubMed ID: 34116943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Achieving efficacy in subjects with sustained pegvaliase-neutralizing antibody responses.
    Aryal M; Lau K; Boyer R; Zhou H; Abend J; Gu K; Olbertz J; Gupta S; Zoog S; Larimore K
    Mol Genet Metab; 2021 Nov; 134(3):235-242. PubMed ID: 34716085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes in 14 live births resulting from Pegvaliase-treated pregnancies in PKU-affected females.
    Bier C; Dickey K; Bibb B; Crutcher A; Sponberg R; Chang R; Boyer M; Davis-Keppen L; Matthes C; Tharp M; Vice D; Cooney E; Morand M; Ray J; Lah M; McNutt M; Andersson HC
    Mol Genet Metab; 2024 Mar; 141(3):108152. PubMed ID: 38367583
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic etiology and clinical challenges of phenylketonuria.
    Elhawary NA; AlJahdali IA; Abumansour IS; Elhawary EN; Gaboon N; Dandini M; Madkhali A; Alosaimi W; Alzahrani A; Aljohani F; Melibary EM; Kensara OA
    Hum Genomics; 2022 Jul; 16(1):22. PubMed ID: 35854334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.